Pulmonary Mycobacterium abscessus infection treated in combination with inhaled tigecycline

Andreas Arnholdt Pedersen*, Andreas Fløe, Anders Løkke, Ole Hilberg

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

16 Downloads (Pure)


Pulmonary disease caused by Mycobacterium abscessus is difficult to treat, as there is currently no reliable evidence-based treatment. Treatment is long, complex and has many side effects. In this case, we report a patient with treatment-refractory pulmonary M. abscessus disease, treated with inhaled tigecycline. Treatment with inhaled tigecycline lasted 15 months with comparably limited side effects. There were no positive mycobacterial cultures in the follow-up period of 2 years. Inhaled tigecycline is an option in the treatment of pulmonary M. abscessus when first-line treatment fails. Additional research should investigate this further.

Original languageEnglish
Article numbere255383
JournalBMJ Case Reports
Issue number12
Number of pages4
Publication statusPublished - 16. Dec 2023

Bibliographical note

Publisher Copyright:
© 2023 BMJ Publishing Group. All rights reserved.


  • Drugs: infectious diseases
  • Infectious diseases
  • Respiratory medicine
  • TB and other respiratory infections


Dive into the research topics of 'Pulmonary Mycobacterium abscessus infection treated in combination with inhaled tigecycline'. Together they form a unique fingerprint.

Cite this